About Us
Chairwoman of the Board, Executive Director: Ms. Theresa Tse
-
- Chairwoman of the Board, Executive Director: Ms. Theresa Tse
- Ms. Theresa Tse is the Chairwoman of the Board of Sino Biopharmaceutical Limited and Vice Chairwoman of CP Pharmaceutical Group since 2015. She is also the Director of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Vice Chairwoman of Beijing Tide Pharmaceutical Co.,Ltd. since 2017. Ms.Tse holds a Bachelor of Science Degree in Economics from the Wharton School of the University of Pennsylvania. Ms. Tse was included in the list of "100 Outstanding Business Women in China" by Forbes China for seven times from 2018 to 2025, and selected as one of "The Bloomberg 50" for 2024 by Bloomberg Businessweek.
Sino Biopharmaceutical Limited was listed on the Hong Kong Stock Exchange in 2000. Guided by the four main strategies of "organizational integration, comprehensive innovation, globalization, and digitalization", the Group focuses on innovation-driven transformation and accelerated international development. Under the leadership of Ms.Tse, Sino Biopharm became a constituent stock of the Hang Seng Index in 2018, and Hang Seng Connect Biotech 50 Index in 2020. It has been seven years in a row among the "Top 50 Global Pharmaceutical Enterprises" named by the US authoritative magazine Pharm Exec and was for three consecutive years among the "Asia's Fab 50 Companies" named by Forbes Asia. The Group upholds the concept of "Science for a healthier world". It currently focuses on four key strategic areas: oncology, liver diseases, respiratory, and surgery/analgesic, and has cumulatively served over 160 million patients. At the same time, the Group continues to increase its investment in innovative drug R&D annually, ranking us 15th globally in terms of pipeline scale.
The innovation transformation is now entering a harvest period, and more innovative products will be launched in the future to fill unmet clinical needs, hoping to provide more effective treatment options for more patients.
While adhering to innovative R&D, Ms. Tse has led Sino Biopharm to actively undertake social responsibilities and participate in various public welfare and charitable activities, implementing the principle of "benefiting the country, the people, and the enterprise". The company has continuously carried out activities in areas such as educational support, rural revitalization, and community welfare. In 2024, the total investment in public welfare amounted to over RMB 60 million . Under the leadership of Ms. Tse, the Group practices the mission of " "Enhancing Life Quality, Upholding Life Dignity". It has carried out multiple innovative ESG practices in corporate governance, environmental protection, and social responsibility, achieving excellent results. As of the end of 2024, the Group has received an "A" rating from the MSCI ESG ratings for two consecutive years.
*Portrait rights belong to the individual. Unauthorized use is prohibited.
-
Blockbuster Deal! $500 Million Acquisition of LaNova Medicines to Further Accelerate Sino Biopharm's Innovation and Internationalization 2025.07
On July 15, Sino Biopharm (1177.HK) made a major announcement that it will acquire 100% of LaNova Medicines Ltd. for a net consideration of approximately US$500 million.View > -
Sino Biopharm Held Briefing on LaNova Medicines Acquisition and Detailed Potential Assets of Four Major Platforms 2025.07
On the morning of July 17, Sino Biopharm, the parent company of Chia Tai Tianqing, held a briefing on the wholly-owned acquisition of LaNova Medicines.View > -
Sino Biopharm Reports Strong H1 Results: Net Profit Doubles, Innovation Drives Record Revenue of RMB 17.57 Billion 2025.08
On the afternoon of August 18, Sino Biopharm (1177.HK) held its interim results conference in Hong Kong, continuing its outstanding performance of high growth in revenue and net profit: In the first half of 2025, the company's revenue reached RMB 17.57 billion, with a year-on-year increase of 10.7%; the net profit attributable to owners of the parent from continuing operations was RMB 3.39 billion, with a substantial increase of 140.2%; and the adjusted net profit attributable to owners of the parent was RMB 3.09 billion, with a year-on-year increase of 101.1%.View >